Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort (medical study)

A new observational study of 197 cancer patients taking a combined ivermectin + mebendazole protocol is going viral on social media — and for understandable reasons. At six-month follow-up, 84.4% of respondents reported clinical benefit (no evidence of disease, regression, or stable disease), and nearly half (48.4%) reported either tumor regression or no current evidence of disease. The combination was well tolerated, with only mild, mostly gastrointestinal side effects. The paper, posted on Zenodo about a week and a half ago, is the largest structured real-world look at this specific repurposed-drug pairing published to date.This post is a summary. The...